4.7 Article

Applying New Diagnostic Criteria for Acute Kidney Injury To Facilitate Early Identification of Nephrotoxicity in Vancomycin-Treated Patients

期刊

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 55, 期 7, 页码 3278-3283

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00173-11

关键词

-

向作者/读者索取更多资源

Acute kidney injury (AKI) associated with high-dose vancomycin (VAN) therapy is a clinical concern, but no uniform diagnostic criteria exist. The AKI Network (AKIN) proposed new criteria to diagnose AKI based on abrupt changes in serum creatinine or urine output. We conducted a prospective observational study to determine the incidence and severity of AKI and associated outcomes using the AKIN criteria versus traditional definitions. Eligible patients (n = 227) were elderly (median, 70 years) and received VAN therapy for 8 days (median). AKI occurred in 43 patients (19%) using AKIN criteria at an onset of 6 days. AKI incidence was similar for patients with a trough level of >= 15 (24%; 17/72) versus <15 (17%; 26/155) mu g/ml. Compared to non-AKI patients, more AKI patients resided in the intensive care unit (ICU) (47% [20/43] versus 27% [50/184]; P = 0.017), had a prior AKI episode (19% [8/43] versus 7% [5/184]; P = 0.001), and received vasopressor (28% [12/43] versus 14% [25/184]; P = 0.04) and/or nephrotoxins (84% [36/43] versus 67% [123/184]; P = 0.04). Seventeen of the AKI patients met traditional criteria, of whom more patients had stage 2 and 3 AKI (76% versus 8%; P = 0.0001), dosage adjustment (41% versus 15%) and renal consultation (35% versus 12%), prolonged length of stay after AKI (11 versus 7.5 days) and died (29% versus 12%) than those diagnosed by AKIN criteria (P value not significant). Use of AKIN criteria for AKI has the potential to improve care of VAN-treated patients by facilitating early detection of AKI and warrants confirmation in large prospective trials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pharmacology & Pharmacy

The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients

Sean N. Avedissian, Nathaniel J. Rhodes, Tien M. H. Ng, Adupa P. Rao, Paul M. Beringer

PHARMACOTHERAPY (2019)

Article Multidisciplinary Sciences

Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms

Virginia Basso, Dat Q. Tran, Justin B. Schaal, Patti Tran, Yoshihiro Eriguchi, Diana Ngole, Anthony E. Cabebe, A. Young Park, Paul M. Beringer, Andre J. Ouellette, Michael E. Selsted

SCIENTIFIC REPORTS (2019)

Article Oncology

Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer

Weijun Wang, Haiping He, Nagore Marin-Ramos, Shan Zeng, Steven D. Swenson, Hee-Yeon Cho, Jie Fu, Paul M. Beringer, Josh Neman, Ligang Chen, Axel H. Schonthal, Thomas C. Chen

Summary: NEO100 facilitates brain tumor entry of trastuzumab and T-DM1, significantly enhancing therapeutic efficacy and increasing antibody-dependent immune cell recruitment.

NEURO-ONCOLOGY (2021)

Article Chemistry, Multidisciplinary

Engineered Cyclotides with Potent Broad in Vitro and in Vivo Antimicrobial Activity

Rajasekaran Ganesan, Mansour A. Dughbaj, Lisa Ramirez, Steven Beringer, Teshome L. Aboye, Alexander Shekhtman, Paul M. Beringer, Julio A. Camarero

Summary: This study reports the development of a novel engineered cyclotide with effective broad-spectrum antibacterial activity against several ESKAPE bacterial strains and clinical isolates. The most active antibacterial cyclotide was extremely stable in serum, showed little hemolytic activity, and provided protection in vivo in a murine model of P. aeruginosa peritonitis. These results highlight the potential of the cyclotide scaffold for the development of novel antimicrobial therapeutic leads for the treatment of bacteremia.

CHEMISTRY-A EUROPEAN JOURNAL (2021)

Correction Oncology

Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brainmetastatic breast cancer (vol 23, pg 1656, 2021)

Weijun Wang, Haiping He, Nagore I. Marin-Ramos, Shan Zeng, Steven D. Swenson, Hee-Yeon Cho, Jie Fu, Paul M. Beringer, Josh Neman, Ligang Chen, Axel H. Schonthal, Thomas C. Chen

NEURO-ONCOLOGY (2021)

Article Microbiology

Preclinical Pharmacokinetics and Safety of Intravenous RTD-1

A. Young J. Park, Dat Q. Tran, Justin B. Schaal, Mengxi Wang, Michael E. Selsted, Paul M. Beringer

Summary: This study characterized the preclinical pharmacokinetics and safety of intravenous RTD-1. The results showed extensive tissue distribution and excellent safety profile for RTD-1, supporting its clinical investigation for the treatment of COVID-19 or other pulmonary inflammatory diseases.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Article Chemistry, Organic

Chemical Synthesis of a Potent Antimicrobial Peptide Murepavadin Using a Tandem Native Chemical Ligation/Desulfurization Reaction

Dipankar Chaudhuri, Rajasekaran Ganesan, Alicia Vogelaar, Mansour A. Dughbaj, Paul M. Beringer, Julio A. Camarero

Summary: A new epimerization-free approach for the Fmoc-based synthesis of murepavadin using intramolecular native chemical ligation and desulfurization reaction has been developed, resulting in a high yield of bioactive murepavadin in two steps. The synthetic peptide antibiotic showed potent activity against different clinical isolates of P. aeruginosa. This approach can be easily adapted for the production of murepavadin analogues and other backbone-cyclized peptides.

JOURNAL OF ORGANIC CHEMISTRY (2021)

Article Pharmacology & Pharmacy

Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19

Eunjin Hong, Lisa M. Almond, Peter S. Chung, Adupa P. Rao, Paul M. Beringer

Summary: Cystic fibrosis patients are at higher risk following COVID-19 infection, and it is crucial to manage the drug-drug interaction between CFTR modulating therapies and COVID-19 treatments. This study used a pharmacokinetic modeling approach to evaluate the interaction and proposed a treatment regimen to minimize its impact.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Article Microbiology

Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria

E. Hong, L. M. Almond, P. S. Chung, A. P. Rao, P. M. Beringer

Summary: This study evaluates the drug-drug interactions between elexacaftor, tezacaftor, and ivacaftor and the NTM treatment drugs in people with cystic fibrosis. Physiologically based pharmacokinetic modeling is used to predict and adjust the dosing regimens, ensuring effective treatment. The study provides evidence for the use of NTM treatment drugs in conjunction with appropriately adjusted doses of cystic fibrosis therapies.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Review Biochemistry & Molecular Biology

Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications

Eunjin Hong, Alan Shi, Paul Beringer

Summary: Cystic fibrosis (CF) is a disease characterized by mucus accumulation, and CFTR modulators significantly improve lung function and nutritional status. However, they can interact with certain enzymes and transporters, leading to potential drug-drug interactions (DDI).

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2023)

Article Pharmacology & Pharmacy

Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series

Eunjin Hong, Regina Li, Alan Shi, Lisa M. Almond, Joshua Wang, Amin Z. Khudari, Soumar Haddad, Sarkis Sislyan, Marissa Angelich, Peter S. Chung, Adupa P. Rao, Paul M. Beringer

Summary: This study provides evidence that reduced doses of Elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis patients who have experienced adverse effects may be effective. The physiologically based pharmacokinetic (PBPK) models enable exploration of a mechanistic basis for this finding by simulating target tissue concentrations of ETI that can be compared with drug efficacy in vitro.

PHARMACOTHERAPY (2023)

Article Pharmacology & Pharmacy

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients

Eunjin Hong, Eugeniu Carmanov, Alan Shi, Peter S. Chung, Adupa P. Rao, Kevin Forrester, Paul M. Beringer

Summary: ETI treatment has potential benefits for lung transplant recipients, but the use of ivacaftor as a part of the treatment may increase the risk of elevated systemic exposure to tacrolimus. This study aims to determine the impact of ETI on tacrolimus exposure and develop an appropriate dosing regimen to manage this drug-drug interaction.

PHARMACEUTICS (2023)

Article Infectious Diseases

Anti-Inflammatory Effects of RTD-1 in a Murine Model of Chronic Pseudomonas aeruginosa Lung Infection: Inhibition of NF-κB, Inflammasome Gene Expression, and Pro-IL-1β Biosynthesis

Mansour A. Dughbaj, Jordanna G. Jayne, A. Young J. Park, Timothy J. Bensman, Marquerita Algorri, Andre J. Ouellette, Michael E. Selsted, Paul M. Beringer

Summary: RTD-1 exhibited potent anti-inflammatory activity in a murine model of chronic P. aeruginosa lung infection, reducing lung white blood cell counts and proinflammatory gene expression, particularly inflammasome-related genes. This immunomodulatory peptide may be a promising therapeutic for CF-associated lung disease.

ANTIBIOTICS-BASEL (2021)

Meeting Abstract Pediatrics

POPULATION MANAGEMENT OF CF ADULTS WITH ACUTE PULMONARY FUNCTION DECLINE

J. Wang, D. Benitez, P. Beringer, A. Rao

PEDIATRIC PULMONOLOGY (2019)

暂无数据